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Abstract 
Purpose: The putative tumour suppressor and apoptosis-promoting gene, growth arrest-
specific 5 (GAS5), encodes lncRNA and snoRNAs. Its expression is down-regulated in breast 
cancer, which adversely impacts patient prognosis. In this preclinical study, the consequences 
of decreased GAS5 expression for breast cancer cell survival following treatment with 
chemotherapeutic agents are addressed. In addition, functional responses of triple-negative 
breast cancer cells to GAS5 lncRNA are examined, and mTOR inhibition as a strategy to 
enhance cellular GAS5 levels is investigated. Methods: Breast cancer cell lines were 
transfected with either siRNA to GAS5 or with a plasmid encoding GAS5 lncRNA and the 
effects on breast cancer cell survival were determined. Cellular responses to mTOR inhibitors 
were evaluated by assaying culture growth and GAS5 transcript levels. Results: GAS5 
silencing attenuated cell responses to apoptotic stimuli, including classical chemotherapeutic 
agents; the extent of cell death was directly proportional to cellular GAS5 levels. Imatinib 
action in contrast, was independent of GAS5. GAS5 lncRNA promoted the apoptosis of 
triple-negative and estrogen receptor-positive cells but only dual PI3K/mTOR inhibition was 
able to enhance GAS5 levels in all cell types. Conclusions: Reduced GAS5 expression 
attenuates apoptosis induction by classical chemotherapeutic agents in breast cancer cells, 
providing an explanation for the relationship between GAS5 expression and breast cancer 
patient prognosis. Clinically, this relationship may be circumvented by the use of GAS5-
independent drugs such as imatinib, or by restoration of GAS5 expression. The latter may be 
achieved by the use of a dual PI3K/mTOR inhibitor, to improve apoptotic responses to 
conventional chemotherapies. 
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Abbreviations:  
A490  Absorbance at 490 nm 
CT   Threshold cycle 
EST  Expressed sequence tag 
5-FU  5-Fluorouracil 
GAS5  Growth arrest-specific 5 
HER2 Human epidermal growth factor receptor 2 
lncRNA Long ncRNA  
MCT  Multiple comparison test 
NC Negative control  
ncRNA Non-coding RNA 
NMD Nonsense-mediated decay 
RT-qPCR Real time reverse transcription polymerase chain reaction 
5′-TOP 5′-Terminal oligopyrimidine tract 
TNBC Triple-negative breast cancer 
UV-C Ultraviolet-C. 
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Introduction 
Long ncRNAs (size range: 0.2 - 100 kb) are emerging as key regulators of fundamental 
cellular processes and are increasingly recognized as of importance in the pathogenesis, 
diagnosis and treatment of major cancers, including breast cancer [1-5]. Apart from 
ribosomal RNAs, lncRNAs comprise a plethora of mRNA-like transcripts (long intergenic 
ncRNAs, pseudogene-derived transcripts and sequences that are intronic or antisense to 
protein coding genes) [1, 6, 7], which can act as signals, scaffolds, guides, decoys or tethers 
to modulate, for example, the maintenance of subcellular structures, chromatin modification 
and transcriptional/post-transcriptional regulation of gene expression [7, 8]. 
 
The lncRNA and small nucleolar RNA (snoRNA) host gene, growth arrest-specific 5 
(GAS5), is of particular interest in breast cancer, since its expression is down-regulated in 
tumour tissue [9], and patient prognosis is related to GAS5 transcript levels [10]. GAS5 is a 
5′-terminal oligopyrimidine tract (5′-TOP) gene, and comprises 12 exons which are 
alternatively spliced to yield two possible mature lncRNAs [11]. GAS5 intronic sequence 
additionally encodes ten distinct box C/D snoRNAs [11]; three of which (U44, U74 and U78) 
may serve as miRNA precursors [12]. Multiple other GAS5 expressed sequence tags (ESTs) 
have also been identified, many of which contain retained introns, indicating that post-
transcriptional processing of GAS5 RNA is complex.  
 
GAS5 transcripts accumulate in growth-arrested cells [11, 13] due to interplay between the 
mTOR pathway (through its regulation of translation of RNAs carrying the 5′-TOP sequence) 
and the nonsense-mediated decay (NMD) pathway (due to the GAS5 short reading frame) 
[11, 14].  Thus, in actively growing cells, where mTOR activity is high, translation of the 
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short reading frame is promoted, resulting in degradation of transcripts by the NMD pathway, 
and consequently low cellular GAS5 lncRNA levels. Suppression of cell growth and mTOR 
activity prevents the active translation of GAS5 transcripts and their consequent degradation 
by NMD, resulting in the accumulation of GAS5 lncRNA [11, 13, 14]. Direct inhibition of 
mTOR activity by rapamycin and rapalogues produces the predicted increase in cellular 
GAS5 lncRNA [11, 15, 16]. 
 
In breast and other cell types, GAS5 inhibits cell proliferation and/or stimulates apoptosis [9, 
17-21], i.e., key determinants of cell survival that are often disrupted in cancer [22]. Indeed, 
elevated GAS5 expression inhibits human breast tumour growth in a xenograft mouse model 
[21], consistent with a tumour suppressor role for this gene. Moreover, the apoptosis-
promoting activity of GAS5 has implications for cancer therapies, since the action of many 
chemotherapeutic drugs ultimately depends on engagement of the cellular apoptotic 
machinery [23, 24]. However, the consequences of reduced GAS5 expression for 
chemotherapeutic drug action in breast cancer cells have not been examined to-date. 
 
In this study we have focussed on the chemotherapeutic implications of reduced GAS5 
expression in breast cancer. Firstly, we have investigated the hypothesis that GAS5 silencing 
impairs the responses of breast cancer cells to apoptotic stimuli. Secondly, we have examined 
whether functional responses to GAS5 remain intact in triple-negative breast cancer (TNBC) 
cells. Finally, we have investigated mTOR inhibition as a strategy to enhance cellular GAS5 
levels in breast cancer cells and consequently to suppress cancer growth through the 
induction of apoptosis and/or cell cycle arrest. 
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Materials and methods 
Material 
Cell lines were from ATCC-LGC Promochem (Teddington, UK). Cell culture materials and 
classical chemotherapeutic drugs were from Sigma-Aldrich Company Ltd (Gillingham, UK). 
Sources of other drugs were: rapamycin (Millipore, Watford, UK); temsirolimus and 
everolimus (LC Laboratories, Woburn, MA); BEZ235 and AZD8055 (Stratech Scientific, 
Newmarket, UK); and imatinib (mesylate) (Cayman Chemical, Ann Arbor, MI). TRIzol, 
reverse transcription reagents, TaqMan assays and Silencer Select siRNAs were from Life 
Technologies Ltd (Paisley, UK). SensiFast Probe Hi-ROX kit was from Bioline (London, 
UK), RQ1 RNase-free DNase and the MTS assay (CellTiter 96 AQueous One Solution Cell 
Proliferation Assay) were from Promega (Southampton, UK), RNAiFect was from Qiagen 
(Crawley, UK) and nucleofector solution V was from Lonza Biosciences (Verviers, 
Belgium). 
 
Methods 
Cell culture 
The breast cancer cell lines MCF7, T-47D and MDA-MB-231 were generated from 
secondary stocks of cells which had been frozen down within two weeks receipt from the 
ATCC. Cells were cultured in R-10 medium (RPMI-1640 supplemented with 2 mM L-
glutamine, 1 mM sodium pyruvate, 10 mM HEPES, 10% fetal bovine serum and 50 µg/ml 
gentamicin) at 37 °C in a humidified incubator with 5% CO2. Cell lines were replaced with 
fresh stocks after a maximum culture period of two months. 
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RNA interference by siRNA 
Cells were transfected with Ambion Silencer Select siRNAs using RNAiFect reagent, 
according to a standard protocol [20]. Up to 4 different GAS5 siRNAs were employed, 
termed siRNAs #1 – 4 (product codes/targeted exons are: n272334/exon 2; n272337/exon 8; 
n272340/exon 12 and n272331/exon 12, respectively); controls received negative control 
(NC) siRNA (code AM4611).  
 
Plasmid DNA transfection 
Plasmids were: pcDNA3/GAS5.O1 (encodes GAS5 O1 EST); pcDNA3/GAS5.AE (encodes 
mature GAS5 lncRNA); and pcDNA3 vector (for controls) [20]. Cells were nucleofected 
with plasmids (2 µg per 2 x 10
6
 cells in 0.1 ml nucleofector solution V) using programmes E-
014 and X-013 for MCF7 and MDA-MB-231, respectively, and cells were plated in 3 ml R-
10 medium in 6-well plates.  
 
Induction of cell death and cell survival assays 
At 72 h post-siRNA transfection or at 20 h post-plasmid nucleofection, cells were 
trypsinized, sampled for RNA, then seeded (0.8 x 10
5
 cells for siRNA-transfected cells; 1.6 x 
10
5
 cells for plasmid-transfected cells) into 12-well plates. Ultraviolet-C (UV-C) irradiation 
was performed prior to plating [20]; doses were 40 J/m
2
 for MCF7 and MDA-MB-231 cells, 
and 60 J/m
2
 for T-47D cells; controls were mock-irradiated. For drug treatments, cells were 
cultured for 20 h, before addition of 5-fluorouracil (5-FU; 175 µM), docetaxel (10 µM), 
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imatinib (50 µM) or vehicle (0.25% dimethyl sulphoxide). Cells were cultured for 48 h post-
treatment, then adherent cells were trypsinized and combined with non-adherent cells for 
analysis of cell survival. 
 
Apoptosis was routinely determined by assessment of nuclear morphology by fluorescence 
microscopy after staining with acridine orange (25 µg/ml); cells containing condensed or 
fragmented chromatin were scored as apoptotic. Cell viability was determined by counting of 
nigrosin blue (0.1% (w/v)) stained samples using a haemocytometer and light microscopy. 
For clonogenic assays, cells were re-plated in culture medium supplemented with 10% (v/v) 
cell-conditioned medium in 6-well plates, cultured for 3 weeks, then the number of colonies 
was counted after staining with crystal violet. 
 
Assessment of mTOR inhibitor sensitivity 
Cells were plated in 96-well plates (500 cells in 0.1 ml R10 medium) and in 12-well plates 
(1.6 x 10
5
 cells in 0.8 ml R10 medium). After 4 h, an equal volume of medium containing the 
appropriate drug or vehicle (final concentrations: 1 µM rapamycin, 10 nM everolimus, 10 nM 
temsirolimus, 100 nM BEZ235, 50 nM AZD8055 or 0.1% dimethyl sulphoxide) was added. 
Experiments were terminated after a further 20 h (12-well plates; for GAS5 determination) or 
70 h (96-well plates; for MTS assay). For the latter, sample absorbance readings at 490 nm 
(A490) were corrected for the appropriate medium plus drug blank values. 
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Effect of cell density-induced growth arrest on cellular GAS5 levels 
For low cell density, logarithmic phase cultures, cells were plated at 2 x 10
5
 per well (6-well 
plate) then harvested after 24 h culture. For high cell density, stationary phase cultures, cells 
plated at 10 x 10
5
 cells per well (6-well plate) then harvested after 96 h culture.  
 
Real time RT-PCR (RT-qPCR) 
TaqMan Gene Expression Assays (assay codes Hs99999901_m1 for 18S and 
Hs03464472_m1 for GAS5) were employed with cDNA prepared by random hexamer 
priming, as described previously [20]. Assays (25 µl) contained 10 ng sample cDNA or 0.2 – 
60 ng standard cDNA (prepared from MCF7 cells). Input amounts of samples were calculated 
from their respective threshold cycle (CT) values, using standard curves generated with each 
assay. Data were expressed relative to 18S rRNA. 
 
Statistical analyses 
Data are presented as the mean ± SEM; the number of observations (n) refers to different 
transfected samples (each from separate cultures) or separate cultures. Data analysis was 
either by an unpaired Student's t-test (when comparing two groups only) or by one-way 
analysis of variance with either Bonferroni's multiple comparison test (MCT) or Dunnett’s 
MCT (when comparing multiple groups versus a single group), as indicated. Homogeneity of 
variance was checked by Bartlett's test and, where necessary, data were transformed (log or 
square root) prior to analysis. The relationship between survival parameters and GAS5 levels 
in cells was analyzed by linear regression. Statistical analyses were performed using 
GraphPad Prism v4.03. 
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Results 
GAS5 silencing attenuates apoptosis induction in breast cancer cells 
To examine the effects of reduced GAS5 expression on breast cancer cell survival, GAS5 
siRNAs were employed to silence endogenous GAS5 expression in two cell lines, MCF7 and 
T-47D; a range of siRNAs were employed to reduce the likelihood of ‘off-target’ effects. The 
influence of GAS5 silencing on cell survival was examined under basal conditions and after 
apoptosis induction by a range of stimuli. 
 
In MCF7 cells, GAS5 siRNAs reduced GAS5 transcript levels by upto one third of control 
levels (Fig. 1a). This had no statistically significant effect on basal apoptosis (Fig. 1b), short-
term viability (Fig. 1d), viable cell number (Fig. 1f) or clonogenic activity (Fig. 1h), as 
judged from mock-irradiated cells. However, GAS5 knockdown attenuated apoptosis 
induction by UV-C irradiation (Fig. 1c) and the consequent reduction in culture viability (Fig. 
1e) and clonogenic activity (Fig. 1i). Growth arrest due to UV-C treatment appeared less 
markedly affected however, as judged from viable cell counts (Fig. 1g). 
 
Consistent with these observations, GAS5 knockdown in T-47D cells (Fig. 2a) diminished 
apoptosis induction by UV-C irradiation (Fig. 2c), as well as the associated losses in culture 
viability (Fig. 2e) and clonogenic activity (Fig. 2i); less robust effects on UV-C-induced 
growth arrest were also noted for this cell line (Fig. 2g).  Basal apoptosis was also reduced by 
GAS5 silencing in T-47D cells (Fig. 2b), in contrast to findings in MCF7 cells (Fig. 1b). This 
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was associated with increased culture viability (Fig. 2d), but basal clonogenic activity was 
unaffected (Fig. 2h).  
 
These findings were confirmed (Figs. 3a & b) in control experiments examining the effects of 
GAS5 silencing on chemotherapeutic drug action. GAS5 silencing diminished docetaxel-
induced apoptosis and the associated loss of culture viability in both MCF7 (Fig. 3c) and T-
47D cells (Fig. 3d). Similar effects were observed regarding 5-FU action in MCF7 (Fig. 3e) 
and T-47D (Fig. 3f) cells, whereas, imatinib action was unaffected by GAS5 silencing (Figs. 
3g & h).  
 
Breast cancer cell survival is related to cellular GAS5 levels 
If impaired responses to chemotherapeutic drugs underlie the clinical relationship between 
patient survival and breast cancer GAS5 levels [10], then parameters of breast cancer cell 
survival should show quantitative relationships with cellular GAS5 levels. Regression 
analysis was therefore performed on data from the GAS5 silencing experiments; cellular 
GAS5 levels were expressed relative to those in negative control siRNA-treated cultures to 
facilitate comparisons between the two cell lines. 
 
Under basal conditions, apoptosis and viability were related to cellular GAS5 levels in T-47D 
cells (Fig. 4b) but not in MCF7 cells (Fig. 4a). Upon treatment with either UV-C irradiation 
(Figs. 4c & d), docetaxel (Figs, 4e & f) or 5-FU (Figs. 4g & h), consistent and statistically 
significant relationships were observed for MCF7 and T-47D cells; apoptosis was 
characterized by a direct relationship—and viability by a corresponding inverse 
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relationship—with cellular GAS5 levels (Figs. 4c – 4h). Parameters of cell survival after 
imatinib treatment were unrelated to cellular GAS5 levels in both cell lines (data not shown). 
 
GAS5 lncRNA is sufficient to induce apoptosis in MCF7 cells 
The transfection of breast cancer cells with GAS5 ESTs promotes apoptosis [9], but it is 
unclear whether mature GAS5 lncRNA is sufficient to mediate this action, as all the effective 
GAS5 ESTs contained retained snoRNAs. Therefore, the cell death-promoting activities of 
mature GAS5 lncRNA (i.e., exons 1 – 12 only) and the GAS5-O1 EST (comprises snoRNA 
U74, 3′ sequence of the first intron and exons 2 – 12) were compared in MCF7 cells.  
 
Transfection of MCF7 cells with each GAS5 construct increased cellular GAS5 levels to a 
similar extent (Fig. 5a). As expected [9], the GAS5-O1 construct increased the proportion of 
apoptotic cells and decreased culture viability (Fig. 5b) at 24 h post-nucleofection; the GAS5-
AE construct, which encodes mature lncRNA, produced a similar quantitative response (Fig. 
5b). Likewise, GAS5-O1 and GAS5-AE constructs stimulated UV-C-induced apoptosis and 
loss of culture viability (Fig. 5c) to a similar extent. Thus, mature GAS5 lncRNA is sufficient 
to promote apoptosis in MCF7 cells. 
 
GAS5 lncRNA also induces apoptosis in triple-negative MDA-MB-231 cells 
Endogenous levels of GAS5 transcripts are reduced in the TNBC cell line, MDA-MB-231, 
relative to estrogen receptor-positive cell lines [9, 21]. To examine if TNBC cells retain 
sensitivity to GAS5 lncRNA, parameters of cell survival were assessed following transfection 
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of MDA-MB-231 cells with the plasmid encoding mature GAS5 lncRNA. Increased GAS5 
levels (Fig. 6a) were associated with increased basal apoptosis and reduced culture viability 
(Fig. 6b) from 24 h post-nucleofection, and also enhanced the death of MDA-MB-231 cells 
upon UV-C-irradiation (Fig. 6c). Thus, triple-negative MDA-MB-231 cells are sensitive to 
GAS5 lncRNA, as for MCF7 cells.  
 
mTOR inhibition modulates GAS5 expression in breast cancer cell lines 
Clinically, the use of mTOR inhibitors may offer a simple method to enhance cellular GAS5 
levels in order to promote the death of breast cancer cells. Therefore, we initially examined 
the effects of rapamycin and related first generation mTOR inhibitors on breast cancer cell 
lines. These agents inhibited the growth of all cell lines by between ca. 20 – 50%; the extent 
of growth inhibition was similar for MCF7 and T-47D cells, but was noticeably smaller for 
MDA-MB-231 cells, irrespective of the applied rapalogue (Fig. 7a). Cellular GAS5 levels 
were enhanced by >50% (P < 0.05; one-way ANOVA and Bonferroni’s MCT) by rapalogue 
treatment of MCF7 and T-47D cells, whereas they were unchanged in MDA-MB-231 cells 
(Fig. 7a). In view of this resistance of MDA-MB-231 cells to first generation mTOR 
inhibitors (which act selectively on mTORC1), we next examined the effects of inhibitors 
with a broader specificity, i.e. the dual mTORC1/mTORC2 inhibitor, AZD8055, and the dual 
PI3K/mTOR inhibitor, BEZ235. The pattern of cell line response to AZD8055 was similar to 
that of rapalogues, whereas BEZ235 markedly inhibited growth and robustly elevated GAS5 
levels in all cell lines (Fig. 7b). 
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Consistent with this insensitivity to rapalogues and AZD8055, MDA-MB-231 cells failed to 
up-regulate cellular GAS5 levels upon cell density-induced growth arrest (Fig. 7c).  In 
contrast, both MCF7 and T-47D cells were characterized by increased GAS5 expression in 
stationary versus logarithmic phases of growth (Fig. 7c).  Further analysis of these data 
confirmed that, in actively growing cultures, levels of GAS5 expression were lower (P < 
0.05; one-way ANOVA and Bonferroni’s MCT) in MDA-MB-231 cells relative to both 
MCF7 and T-47D cells, as previously reported [9]. 
 
Discussion 
The development of targeted therapies has revolutionised the treatment of hormone receptor-
positive and human epidermal growth factor receptor 2 (HER2)-positive breast cancer, but 
resistance to these therapies remains problematic [25, 26]. Furthermore, there currently exists 
no approved targeted therapy for TNBC (lacks estrogen receptor, progesterone receptor and 
HER2 amplification), which frequently exhibits highly malignant behaviour and resistance to 
conventional chemotherapies [27]. The identification of novel therapeutic targets for multiple 
breast cancer subtypes is therefore important, and lncRNAs may offer new opportunities in 
this regard, given their emerging roles as regulators of fundamental biological processes [1-
5]. Indeed, GAS5 is already of particular interest in relation to breast cancer, since its 
expression is down-regulated in tumour tissue [9], and patient prognosis is significantly 
related to GAS5 transcript levels [10]. Current findings in preclinical models demonstrate 
here, for the first time, that breast cancer cell responses to several apoptotic stimuli are 
quantitatively related to cellular GAS5 levels, suggesting a potential functional basis for the 
latter clinically important relationship. The cytotoxic action of certain drugs, such as 
imatinib, is shown to be GAS5–independent, thereby suggesting a way to bypass the 
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relationship to improve patient outcomes. Importantly, a possible therapeutic role for GAS5 
lncRNA in TNBC is identified and, in this regard, dual PI3K/mTOR inhibition is 
demonstrated to be effective in increasing GAS5 levels in such cells.     
 
Although functional studies have previously reported that GAS5 transcripts exert apoptosis-
promoting effects in breast cancer cells and in a range of other cell types [9, 15, 18-21], the 
consequences of reduced GAS5 expression for breast cancer cell survival have not been 
addressed. Here we demonstrate that reductions in GAS5 expression of ca. 50 - 70% in MCF7 
and T-47D cells are consistently associated with attenuated cell death in response to a range 
of apoptosis-inducing agents (UV-C irradiation, 5-FU and docetaxel). Crucially, as in recent 
experiments with prostate cancer cells [20], both the extent of apoptosis induction and the 
associated loss of culture viability are quantitatively related to the extent of GAS5 silencing. 
Thus, even small reductions in endogenous GAS5 expression may adversely impact upon the 
responses of breast cancer cells to certain death-inducing stimuli, including conventional 
chemotherapeutic agents, and this resistance to therapy may explain why breast cancer 
patient survival is related to tumour GAS5 levels [10]. 
 
Imatinib, which provides targeted therapy through inhibition of receptor and non-receptor 
tyrosine kinases (e.g., PDGF receptors, c-kit, c-Abl and Arg) in contrast, efficiently induced 
apoptosis in both MCF7 and T-47D cells, irrespective of cellular GAS5 levels. Thus GAS5 
selectively modulates the action of chemotherapeutic agents, perhaps related to their differing 
mechanisms of engagement of the apoptotic machinery, as suggested by the additive or 
synergistic nature of imatinib action with a range of conventional chemotherapeutic agents 
[28-30]. From a therapeutic perspective, the use of GAS5-independent drugs may offer an 
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improved strategy for breast cancer patients with reduced GAS5 expression, albeit further 
work is required to identify additional chemotherapeutic agents which act in a GAS5-
independent manner in breast cancer cells.  
 
An alternative approach may be to enhance cellular GAS5 levels prior to, or concomitant 
with, the administration of conventional chemotherapies, in order to improve cytotoxic drug 
action. Current findings confirm that GAS5 lncRNA (rather than GAS5-derived snoRNA 
sequence) is sufficient for apoptosis-promoting activity, and further demonstrate that GAS5 
lncRNA is active in the TNBC cell line, MDA-MB-231, which exhibits lower endogenous 
GAS5 levels than estrogen receptor-positive cell lines. Consequently, the proposed approach 
may be beneficial in TNBC, the treatment of which remains especially challenging [27]. Such 
a therapeutic goal could be achieved by a direct approach, involving, for example, gene 
therapy with vectors encoding GAS5 lncRNA, but the clinical application of such therapies in 
general, remains a long term prospect. Since a conventional pharmacological approach would 
be preferable in the short term, we focussed here on the mTOR pathway, which is involved in 
the physiological regulation of cellular GAS5 levels [11, 14]. Only the dual PI3K/mTOR 
inhibitor, BEZ235, elevated GAS5 levels in all cell lines.  
 
The reasons for the resistance of GAS5 transcript levels to mTOR inhibition in MDA-MB-
231 cells is unknown. This cell line also failed to increase GAS5 transcript levels upon cell 
density-induced growth arrest, suggesting a defect in the physiological mechanism of mTOR-
mediated regulation of GAS5. Mutation of the 5’-TOP sequence can be excluded however, 
since the sequence of GAS5 exon 1 (contains the 5’-TOP) in MDA-MB-231 cells is identical 
to that of the NCBI Reference Sequence, NR_002578.2 (data not shown). The mTOR 
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inhibitors are in increasing clinical use and resistance to such agents is becoming increasingly 
evident. The growth of MDA-MB-231 cells has been noted to exhibit reduced sensitivity to 
rapalogues [31-33], as also noted in our study. Nevertheless, basal-like cell lines are not 
totally unresponsive to mTOR inhibitors, since their death can be synergistically enhanced by 
combining such agents with cisplatin [34]. A striking finding in our study, however, was that 
GAS5 levels in MDA-MB-231 cells showed complete resistance to mTORC1 inhibition by 
rapalogues and to dual mTORC1/mTORC2 inhibition by AZD8055. In contrast, they 
displayed a significant increase in response to the dual PI3K/mTOR inhibitor, BEZ235, 
suggesting that mTOR-independent induction of GAS5 may prove a more productive 
approach to improving the therapy of advanced breast cancers. 
 
Conclusions 
The extent of breast cancer cell death consequent upon exposure to certain chemotherapeutic 
drugs and other apoptotic stimuli is directly related to cellular GAS5 levels, implicating 
regulation of apoptosis as the functional role that links GAS5 expression levels with patient 
survival. The use of novel targeted therapies which act independently of GAS5, or 
combination therapies comprising conventional chemotherapeutics coupled with agents to 
enhance cellular GAS5 lncRNA levels, in breast tumours could prove beneficial in improving 
patient outcomes. In this regard, a wide range of mTOR inhibitors may prove useful in 
patients with receptor-positive disease, whereas treatment options may be limited to dual 
PI3K/mTOR inhibitors in TNBC patients.  Findings here in breast cancer cell lines may be 
relevant to the therapy of a wide range of other cancers, including head and neck squamous 
cell carcinoma [10], glioblastoma multiforme [35], renal clear cell carcinoma [36], bladder 
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cancer [37], pancreatic cancer [38] and non-small-cell lung cancer [39], all of which are 
characterized by deficient GAS5 expression. 
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Figure legends 
Fig. 1 Effect of GAS5 siRNA on basal survival and UV-C-induced cell death in MCF7 cells. 
MCF7 cells (n = 5 cultures) were transfected with the indicated GAS5 siRNA or negative 
control (NC) siRNA and harvested at 72 h post-transfection. Cells were treated ± UV-C 
irradiation and replated for assessment of cell survival after a further 48 h. RT-qPCR analysis 
confirmed decreased cellular GAS5 levels at 72 h post-transfection in cells treated with 
GAS5 siRNAs (a). Silencing of GAS5 has no statistically significant effect on basal apoptosis 
in MCF7 cells (b), whereas it attenuates UV-C-induced apoptosis (c). Correspondingly, 
viability is not significantly affected in control cells (d), but it is enhanced in UV-C-treated 
cells (e). Viable cell numbers are not significantly affected in both control (f) and UV-C-
treated (g) cells. Clonogenic activity is also unaffected in control cells (h) but it is enhanced 
in UV-C-treated cells (i). *P < 0.05 & **P < 0.01 versus cells transfected with NC siRNA 
(one-way ANOVA and Dunnett’s MCT) 
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Fig. 2 Effect of GAS5 siRNA on basal survival and UV-C-induced cell death in T-47D cells. 
T-47D cells (n = 4 cultures) were transfected with the indicated GAS5 siRNA or negative 
control (NC) siRNA and harvested at 72 h post-transfection. Cells were treated ± UV-C 
irradiation and replated for assessment of cell survival after a further 48 h. RT-qPCR analysis 
confirmed decreased cellular GAS5 levels at 72 h post-transfection in cells treated with 
GAS5 siRNAs (a). Silencing of GAS5 reduces both basal (b) and UV-C-induced apoptosis 
(c). Correspondingly, viability is enhanced in control (d) and UV-C-treated cells (e). Viable 
cell numbers are not significantly affected in both control (f) and UV-C-treated (g) cells. 
Clonogenic activity is unaffected in control cells (h) but it is enhanced in UV-C-treated cells 
(i). *P < 0.05, **P < 0.01 & ***P < 0.001 versus cells transfected with NC siRNA (one-way 
ANOVA and Dunnett’s MCT) 
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Fig. 3 Effect of GAS5 silencing on chemotherapeutic drug-induced death of breast cancer cell 
lines. MCF7 and T-47D cells (n = 5 cultures) were transfected with the indicated GAS5 
siRNA or negative control (NC) siRNA and, after 72 h, exposed to chemotherapeutic agents 
or vehicle for 48 h. For all figure parts, apoptosis is displayed in the left-hand panel and 
culture viability in the right-hand panel. For vehicle controls, GAS5 silencing had negligible 
effects overall on apoptosis and culture viability in MCF7 cells (a), whereas it reduced 
apoptosis and increased culture viability in T-47D cells (b).  For docetaxel treatment, prior 
GAS5 silencing resulted in consistent and corresponding effects on apoptosis and culture 
viability in both MCF7 (c) and T-47D cells (d). Similar effects were observed for 5-FU 
treatment of MCF7 (f) and T-47D (g) cells, whereas induction of cell death by imatinib was 
unaffected by GAS5 silencing in both cell lines (h and i, respectively). *P < 0.05 & **P < 
0.01 versus cells transfected with NC siRNA (one-way ANOVA and Dunnett’s MCT) 
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Fig. 4 Parameters of cell survival are related to cellular GAS5 levels in breast cancer cell 
lines. Regression analysis was performed for data from Figs. 1 – 3 against cellular GAS5 
levels normalized relative to control (NC siRNA) values; for all figure parts, apoptosis is 
displayed in the left-hand panel and culture viability in the right-hand panel. In the absence of 
any exogenous apoptotic stimulus, apoptosis and culture viability were unrelated to GAS5 
levels in MCF7 cells (a), whereas apoptosis was directly related to—and culture viability was 
inversely related to—cellular GAS5 levels in T-47D cells (b). Apoptosis and culture viability 
were also related to GAS5 levels in both MCF7 and T-47D cells upon exposure to the 
apoptotic stimuli: UV-C irradiation (c & d); docetaxel (e & f); and 5-FU (g & h) 
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Fig. 5 Comparison of the effects of GAS5 ncRNA constructs on the survival of MCF7 cells, 
both basally and after UV-C-induced apoptosis. Cells (n = 4) were transfected with GAS5 
constructs corresponding to mature lncRNA (exons 1 – 12; AE), the GAS5.O1 EST (snoRNA 
U74 plus exons 2 – 12; O1), or empty pcDNA3 vector (V) as control. After 24 h, cells were 
treated ± UV-C irradiation then re-sampled after a further 48 h. a) Cellular GAS5 levels at 24 
h post-transfection are increased to a similar extent by GAS5 O1 and AE constructs. b) At 24 
h post-transfection, the two GAS5 constructs result in similar increases in basal apoptosis 
(left-hand panel) and similar decreases in basal culture viability (right-hand panel). c) The 
two GAS5 constructs exhibit similar potency in enhancing both UV-C-induced apoptosis 
(left-hand panel) and the associated loss in culture viability (right-hand panel). *P < 0.05 & 
***P < 0.001 versus cells transfected with pcDNA3 alone (one-way ANOVA and 
Bonferroni’s MCT)  
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Fig. 6 GAS5 lncRNA is pro-apoptotic in MDA-MB-231 cells. Cells (n = 4) were transfected 
with a construct encoding mature lncRNA (AE) or empty pcDNA3 vector (V) as control and, 
after 24 h, cells were treated ± UV-C irradiation, then re-sampled after a further 48 h. a) 
Cellular GAS5 levels at 24 h post-transfection are increased by the GAS5 AE construct. b) 
GAS5 lncRNA increases basal apoptosis (left-hand panel) and reduces culture viability 
(right-hand panel) at 24 h post-transfection. c) GAS5 lncRNA increases UV-C-induced 
apoptosis (left-hand panel) and the associated loss of culture viability. *P < 0.05 & ***P < 
0.001 versus cells transfected with pcDNA3 alone (Student’s t-test [a & b] or one-way 
ANOVA and Bonferrroni’s MCT [c]) 
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Fig. 7 Effects of pharmacological and physiological inhibitors of mTOR activity in breast 
cancer cell lines. a) Effect of rapamycin (1 µM; R), everolimus (10 nM; E) and temsirolimus 
(10 nM; T) on culture growth (at 70 h; left-hand panel) and GAS5 levels (at 20 h; right-hand 
panel). Data are expressed relative to the vehicle control; *P < 0.05 and **P < 0.01 versus 
MDA-MB-231 cells (one-way ANOVA and Bonferrroni’s MCT; n = 4 cultures). b) Effect of 
AZD8055 (50 nM) and BEZ235 (100 nM) on culture growth (at 70 h; left-hand panel) and 
GAS5 levels (at 20 h; right-hand panel). Data are expressed relative to the vehicle control; 
**P < 0.01 and ***P < 0.001 versus MDA-MB-231 cells and 
++
P < 0.01 versus MCF7 cells 
(one-way ANOVA and Bonferrroni’s MCT; n = 4 cultures). c) Effect of cell density-induced 
growth arrest on cellular GAS5 levels; cells were harvested at logarithmic (log) and 
stationary (stat) phases of growth; **P < 0.01 and ***P < 0.001 versus logarithmic phase 
cultures (one-way ANOVA and Bonferrroni’s MCT; n = 4 cultures) 
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